Otology and neuro-otology: Edited by Myles L. PensakStereotactic radiation treatment of vestibular schwannoma: indications, limitations, and outcomesConley, George S; Hirsch, Barry EAuthor Information Department of Otolaryngology, Eye and Ear Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA Correspondence to Dr Barry E. Hirsch, Department of Otolaryngology, Eye and Ear Institute, 203 Lothrop, Suite #500, Pittsburgh, PA 15213, USA Tel: +1 412 647 2115; fax: +1 412 647 2080; e-mail: firstname.lastname@example.org Current Opinion in Otolaryngology & Head and Neck Surgery: October 2010 - Volume 18 - Issue 5 - p 351-356 doi: 10.1097/MOO.0b013e32833c71a2 Buy Metrics Abstract Purpose of review Stereotactic radiation treatment is an increasingly performed procedure for patients with vestibular schwannoma and other benign skull base tumors. During the past 30 years, advancements in stereotactic imaging, radiation delivery techniques, and dose planning have improved overall patient outcomes. The specific role of radiation in current management strategies for vestibular schwannoma continues to evolve as long-term outcome data are analyzed and standardized studies are performed. The recent literature regarding the indications, limitations, and outcomes for stereotactic radiation treatment is reviewed. Recent findings Systematic reviews of the Gamma Knife literature demonstrate improved overall outcomes with radiation doses below 13 Gy. Observation of small vestibular schwannomas is recommended over early radiation or microsurgical intervention. Radiation may be used as adjunctive therapy for large tumors and in certain postradiation treatment failures. Stereotactic radiosurgery and fractionated radiotherapy are equally effective treatment modalities. Summary Long-term outcome data will ultimately define future indications and limitations for the use of stereotactic radiation with benign skull base lesions. Current evidence supports its use for small to medium sized primary and recurrent vestibular schwannomas with optimal dosing below 13 Gy. It is also recommended for adjunctive therapy, recurrent tumors, in poor surgical candidates, and for those who do not desire observation or surgery. © 2010 Lippincott Williams & Wilkins, Inc.